Ads
related to: cll stage c survival- CLL/SLL Dosing Guidelines
Get Dosing & Prescribing Info
For A CLL Treatment.
- Educational Materials
Find A Selection Of Resources To
Help Your Patients With CLL
- CLL/SLL Efficacy Data
Find Data From Clinical
Trials Of A CLL/SLL Treatment
- Mechanism Of Action
Learn More About Treatment-Related
Lymphocytosis In A CLL Trial
- Patient Support Program
Offers Information & Resources Your
Patients May Need During Treatment.
- CLL/SLL Safety Data
Find Important Safety
Information Of A CLL/SLL Treatment
- CLL/SLL Dosing Guidelines
Search results
Results from the WOW.Com Content Network
Many people with CLL lead normal and active lives for many years—in some cases for decades. Because of its slow onset, asymptomatic early-stage CLL (Rai 0, Binet A) is, in general, not treated since it is believed that early-stage CLL intervention does not improve survival time or quality of life.
About 1-10% of CLL/SLLs develop a Richter's transformation at a rate of 0.5–1% per year. In earlier studies, the transformed disease was reported to be far more aggressive than CLL/SLL with overall median survival times (i.e. times in which 50% of cases remain alive) between 1.1 and 16.3 months.
However, the shortened survival times in high-count CLL/SLL MBL does not appear due to its progression to CLL/SLL. Rather, this shortened survival appears due to the disorders' susceptibility to serious infections, other types of cancers, immune cytopenias, and renal disease.
Specialty. Hematology and oncology. Plasma cell leukemia ( PCL) is a plasma cell dyscrasia, i.e. a disease involving the malignant degeneration of a subtype of white blood cells called plasma cells. It is the terminal stage and most aggressive form of these dyscrasias, constituting 2% to 4% of all cases of plasma cell malignancies.
Acute lymphoblastic leukemia is notable for being the first disseminated cancer to be cured. Survival for children increased from under 10% in the 1960s to 90% in 2015. Survival rates remain lower for babies (50%) and adults (35%).
The 5-year survival rate for children and adolescents under the age of 15 years diagnosed with ALL was 91.8% in the USA between 2007 and 2013. The survival rate for children under the age of 5 years with ALL was 94% during the same time period. Prognostic factors in ALL:
Ads
related to: cll stage c survival